Protalix BioTherapeutics, Inc. has completed a private stock placement
March 2020 — Protalix BioTherapeutics, Inc. has raised funds to refinance the company for further development.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received the approval of the US Food and Drug Administration, for the treatment of Gaucher disease.
Our role in the transaction
Oaklins’ team in Israel advised Protalix BioTherapeutics, Inc. and acted as a member in the distributors’ consortium.
Talk to the deal team
Related deals
Bolster Investment Partners has secured debt financing for the acquisition of Royal Taste Company
Bolster Investment Partners has partnered with Royal Taste Company, a leading Dutch custom signature coffee platform offering end-to-end sourcing, blending, roasting, packaging and delivery services. The partnership marks an important next step in Royal Taste Company’s growth trajectory, focused on further geographical expansion, commercial development and selective strategic acquisitions.
Learn moreUKAT Group has acquired Bayberry Limited
UK Addiction Treatment (UKAT) Group, a leading UK provider of residential addiction, mental health and behavioral health treatment backed by Sullivan Street Partners, has acquired Bayberry Limited, a specialist mental health and wellbeing treatment provider. Joining UKAT enables Bayberry to preserve continuity of care for patients and referral partners, retain the strength of its clinical team and benefit from UKAT’s operational infrastructure, referral network and marketing channels. This partnership supports Bayberry’s next stage of development while preserving the qualities that differentiate its service offering.
Learn moreBerner Group has completed a US$23.4 million private credit financing
Berner Group has successfully closed a US$23.4 million secured private credit facility to fund the repositioning of a former rehabilitation clinic into a student housing scheme in the Rhine-Main region of Germany. The financing was provided by a private debt fund, and structured across three tranches to address the specific requirements of the transaction, including the refinancing of existing bank facilities, funding of capital expenditure and operating costs during lease-up and a conditional tranche linked to the completion of fire safety and remediation works. The deal was structured with a comprehensive security package comprising a first-ranking land charge, share pledge and subordination agreements with existing lenders. Approximately 1% cash equity was contributed by the sponsor, reflecting the strength of the underlying asset and business plan.
Learn more